HOME >> MEDICINE >> NEWS
Newer diabetic meds cost more, but users have fewer hospital visits

Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the market for several decades.

A new study suggests that patients on the newer medications had a slightly lower risk of hospitalization because of diabetes-related complications. They also spent between $920 and $1,760 less on annual total healthcare costs.

The researchers analyzed more than three years' worth of medical records' data on patients who took thiazolidinediones (TZDs) or either metformin or a sulfonylurea to control their diabetes. TZDs (pioglitazone and rosiglitazone, brand names Actos and Avandia, respectively), were approved by the Food and Drug Administration in the late 1990s. Metformin and sulfonylureas have been on the market for more than 50 years.

"Taking a TZD as instructed was the strongest predictor of a reduced risk of hospitalization and decreased healthcare costs in this group of patients," said Rajesh Balkrishnan, the study's lead author and the Merrell Dow professor of pharmacy at Ohio State University.

The issue is that TZDs can be 10 times more expensive than the older diabetes drugs, Balkrishnan said.

"There are a lot of new medications on the market for treating diabetes," Balkrishnan said. "Although some of these newer drugs are more expensive, that extra expense is made up for by a reduction of cost in other aspects of healthcare use."

The study appears in a recent issue of the journal Current Medical Research and Opinion.

The researchers collected information on 3,191 adults enrolled in the North Carolina Medicaid program, which covers all medical and prescription costs of its enrollees. All of the participants had Type 2 diabetes and started medications for the disease between July 2001 and December 2003.

The enrollees were divided into two groups based on the type of drug th
'"/>

Contact: Rajesh Balkrishnan
Balkrishnan.1@osu.edu
614-292-6415
Ohio State University
21-Mar-2006


Page: 1 2 3

Related medicine news :

1. Newer biomarkers add small improvement in cardiovascular risk prediction to established risk factors
2. Newer chemotherapies improve outcomes for some types of breast cancer
3. Newer form of cardiac imaging providing better look at heart
4. Newer imaging techniques may lead to over-treatment
5. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
6. When it comes to preventing amputation in diabetics, site, not size, matters
7. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
8. UW study tests topical honey as a treatment for diabetic ulcers
9. Simple classification can help define and predict limb-threatening diabetic infections
10. Glucose levels trigger compensation for type 2 diabetics
11. Drug treatment slows macular vision loss in diabetics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2016)... ... ... May 26, 2016- In search of the K. Warriors, Shaolin Institute is ... Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West Interstate 65 ... by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is the 28th ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon ... to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel ... year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at ...
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... her award on May 18 at the university’s Student Leadership Awards ceremony. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... thousands of defective respirators, according to court documents and SEC filings. A ... and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
Breaking Medicine Technology:
Cached News: